Dr. Lewis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6800 West Loop S
Ste 560
Bellaire, TX 77401Phone+1 713-778-1300Fax+1 713-778-0827
Education & Training
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1994 - 1997
McGovern Medical School at UTHealthClass of 1994
Certifications & Licensure
TX State Medical License 1997 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Practice Fusion EHR, Practice Fusion, Inc., 2012
Clinical Trials
- Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1 Start of enrollment: 2008 Aug 01
- Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers Start of enrollment: 2011 Feb 01
- Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsEfficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study.Joseph Gathe, Robin L Hardwicke, Fernando Garcia, Steven Weinheimer, Stanley T. Lewis
Journal of Acquired Immune Deficiency Syndromes. 2021-04-01 - 133 citationsPhase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.Brinda Emu, Jeffrey Fessel, Shannon Schrader, Princy Kumar, Gary Richmond
The New England Journal of Medicine. 2018-08-16 - 24 citationsThe efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatmentW. Jeffrey Fessel, Brooke Anderson, Stephen Follansbee, Mark A. Winters, Stanley Lewis
Antiviral Research. 2011-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
